Enliven Therapeutics ELVN Interest coverage
Interest coverage at other companies
Other financials
Where this comes from
Calculated from Enliven Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: Enliven Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Enliven Therapeutics's interest coverage.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Enliven Therapeutics's interest coverage?
- Enliven Therapeutics (ELVN) reported interest coverage of -6.8× in Q1 2026.
- How has Enliven Therapeutics's interest coverage changed year-over-year?
- Enliven Therapeutics's interest coverage increased by 8.4% year-over-year, from -7.4× to -6.8×.
- What is the long-term trend for Enliven Therapeutics's interest coverage?
- Over 5 years (2020 to 2025), Enliven Therapeutics's interest coverage has grown at a -38.7% compound annual growth rate (CAGR), from -86.3× to -7.5×.
- What does interest coverage mean?
- Trailing-twelve-month operating income (EBIT) divided by interest expense. Measures how many times over the company can cover its interest payments from operating profit.